Health Care Ruling Could Mean Years Of Delay For Biosimilars

Law360, New York (June 14, 2012, 10:17 PM EDT) -- If the U.S. Supreme Court decides to strike down the entire health care law it could delay the debut of biosimilars onto the U.S. market for months or even years — along with their potential to cut billions of dollars from the country's total drug spending — especially if Congress devolves into partisan squabbling over re-enacting the biosimilars provisions. 

If the Patient Protection and Affordable Care Act goes down in its entirety, a possibility many court observers see as unlikely but still very real, so too...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.